EP3572406A1 — Acid addition salt of elagolix and related compounds
Assigned to Sandoz AG · Expires 2019-11-27 · 6y expired
What this patent protects
The current invention discloses preparation of acid addition salts of 4-[2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-1,2,3,6-tetrahydro-1-pyrimidinyl]-1(R)-phenylethylamino]butyric acid by treatment of an acid-sensitive ester of , 4-[…
USPTO Abstract
The current invention discloses preparation of acid addition salts of 4-[2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-1,2,3,6-tetrahydro-1-pyrimidinyl]-1(R)-phenylethylamino]butyric acid by treatment of an acid-sensitive ester of , 4-[2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-1,2,3,6-tetrahydro-1-pyrimidinyl]-1 (R)-phenylethylamino]butyric acid with a sufficiently strong acid and subsequent isolation by filtration. The process of the invention prevents formation of (R)-5-(2-fluoro-3-methoxyphenyl)-1-(2-fluoro-6-(trifluoromethyl)benzyl)-6-methyl-3-(2-(2-oxopyrrolidin-1-yl)-2-phenylethyl)pyrimidine-2,4(1H,3H)-dione (Va).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.